Rila Therapeutics helps with anti-fibrotic treatments, focusing on a groundbreaking HIPK2 inhibitor for kidney fibrosis.
Rila Therapeutics has raised $7.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in January 2025.
Rila Therapeutics's investors include ShangPharma Innovation.
Rila Therapeutics is headquartered in San Francisco, United States.
Rila Therapeutics helps with anti-fibrotic treatments, focusing on a groundbreaking HIPK2 inhibitor for kidney fibrosis.
Rila Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rila Therapeutics — Funding & Investors." VCBacked, January 6, 2025, https://www.vcbacked.co/company/rila-therapeutics. Accessed August 15, 2026.
VCBacked. (2025). Rila Therapeutics — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/rila-therapeutics
{{cite web |title=Rila Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/rila-therapeutics |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated